Literature DB >> 16105887

Relation between viral fitness and immune escape within the hepatitis C virus protease.

J Söderholm1, G Ahlén, A Kaul, L Frelin, M Alheim, C Barnfield, P Liljeström, O Weiland, D R Milich, R Bartenschlager, M Sällberg.   

Abstract

BACKGROUND: The hepatitis C virus (HCV) mutates within human leucocyte antigen (HLA) class I restricted immunodominant epitopes of the non-structural (NS) 3/4A protease to escape cytotoxic T lymphocyte (CTL) recognition and promote viral persistence. However, variability is not unlimited, and sometimes almost absent, and factors that restrict viral variability have not been defined experimentally. AIMS: We wished to explore whether the variability of the immunodominant CTL epitope at residues 1073-1081 of the NS3 protease was limited by viral fitness. PATIENTS: Venous blood was obtained from six patients (four HLA-A2+) with chronic HCV infection and from one HLA-A2+ patient with acute HCV infection.
METHODS: NS3/4A genes were amplified from serum, cloned in a eukaryotic expression plasmid, sequenced, and expressed. CTL recognition of naturally occurring and artificially introduced escape mutations in HLA-A2-restricted NS3 epitopes were determined using CTLs from human blood and genetically immunised HLA-A2-transgenic mice. HCV replicons were used to test the effect of escape mutations on HCV protease activity and RNA replication.
RESULTS: Sequence analysis of NS3/4A confirmed low genetic variability. The major viral species had functional proteases with 1073-1081 epitopes that were generally recognised by cross reactive human and murine HLA-A2 restricted CTLs. Introduction of mutations at five positions of the 1073-1081 epitope prevented CTL recognition but three of these reduced protease activity and RNA replication.
CONCLUSIONS: Viral fitness can indeed limit the variability of HCV within immunological epitopes. This helps to explain why certain immunological escape variants never appear as a major viral species in infected humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105887      PMCID: PMC1856491          DOI: 10.1136/gut.2005.072231

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  58 in total

1.  Analysis of a successful immune response against hepatitis C virus.

Authors:  S Cooper; A L Erickson; E J Adams; J Kansopon; A J Weiner; D Y Chien; M Houghton; P Parham; C M Walker
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

2.  Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation.

Authors:  R Bartenschlager; V Lohmann; T Wilkinson; J O Koch
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

3.  Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus.

Authors:  K M Chang; B Rehermann; J G McHutchison; C Pasquinelli; S Southwood; A Sette; F V Chisari
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

4.  Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome.

Authors:  P A Wentworth; A Sette; E Celis; J Sidney; S Southwood; C Crimi; S Stitely; E Keogh; N C Wong; B Livingston; D Alazard; A Vitiello; H M Grey; F V Chisari; R W Chesnut; J Fikes
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

5.  Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities.

Authors:  Georg M Lauer; Kei Ouchi; Raymond T Chung; Tam N Nguyen; Cheryl L Day; Deborah R Purkis; Markus Reiser; Arthur Y Kim; Michaela Lucas; Paul Klenerman; Bruce D Walker
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Authors:  B Rehermann; K M Chang; J G McHutchison; R Kokka; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

7.  Immune responses to the hepatitis C virus NS4A protein are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex.

Authors:  Z X Zhang; M Chen; C Hultgren; A Birkett; D R Milich; M Sällberg
Journal:  J Gen Virol       Date:  1997-11       Impact factor: 3.891

8.  Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers.

Authors:  X S He; B Rehermann; F X López-Labrador; J Boisvert; R Cheung; J Mumm; H Wedemeyer; M Berenguer; T L Wright; M M Davis; H B Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

9.  Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication.

Authors:  Peter Friebe; Julien Boudet; Jean-Pierre Simorre; Ralf Bartenschlager
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

10.  HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice.

Authors:  S Pascolo; N Bervas; J M Ure; A G Smith; F A Lemonnier; B Pérarnau
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

View more
  42 in total

1.  Three-dimensional structure determines the pattern of CD4+ T-cell epitope dominance in influenza virus hemagglutinin.

Authors:  Samuel J Landry
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

Review 2.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

3.  Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen design.

Authors:  Ahmed A Quadeer; Raymond H Y Louie; Karthik Shekhar; Arup K Chakraborty; I-Ming Hsing; Matthew R McKay
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

4.  Vaccines: a moving target.

Authors:  Michael Eisenstein
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

Review 5.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

6.  Optimal viral immune surveillance evasion strategies.

Authors:  Alexandra Agranovich; Tal Vider-Shalit; Yoram Louzoun
Journal:  Theor Popul Biol       Date:  2011-09-02       Impact factor: 1.570

7.  Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.

Authors:  Silvana Gaudieri; Andri Rauch; Lawrence P Park; Elizabeth Freitas; Susan Herrmann; Gary Jeffrey; Wendy Cheng; Katja Pfafferott; Kiloshni Naidoo; Russell Chapman; Manuel Battegay; Rainer Weber; Amalio Telenti; Hansjakob Furrer; Ian James; Michaela Lucas; Simon A Mallal
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

8.  Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs.

Authors:  Shadi Salloum; Cesar Oniangue-Ndza; Christoph Neumann-Haefelin; Laura Hudson; Silvia Giugliano; Marc aus dem Siepen; Jacob Nattermann; Ulrich Spengler; Georg M Lauer; Manfred Wiese; Paul Klenerman; Helen Bright; Norbert Scherbaum; Robert Thimme; Michael Roggendorf; Sergei Viazov; Joerg Timm
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

Review 9.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Authors:  G Ahlén; E Derk; M Weiland; J Jiao; N Rahbin; S Aleman; D L Peterson; K Pokrovskaja; D Grandér; L Frelin; M Sällberg
Journal:  Gut       Date:  2008-08-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.